Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence

IL-15 免疫疗法对组织特异性 CD8 T 细胞的影响,以减少中枢神经系统 HIV 储存库的播种和持久性

基本信息

项目摘要

PROJECT SUMMARY HIV persists long-term in the central nervous system (CNS) even in the presence of antiretroviral therapy (ART). One strategy to target HIV reservoirs in the CNS is to develop interventions aimed at enhancing the breadth and magnitude of CD8 T cells, which can penetrate and persist in the brain as tissue resident cells. Our group has shown that HIV-specific CD8 T cells can limit HIV reservoir seeding in acute infection in the periphery when ART is initiated during acute infection. We have developed unique tools to analyze these cells in the cerebrospinal fluid (CSF) and showed that HIV-specific CD8 T cells can also be detected in the CSF during acute HIV infection and persist in the CSF for up to 2 years after ART initiation. Importantly, the presence of these HIV-specific CD8 T cells is beneficial for limiting neuroinflammation but not enough to fully eliminate HIV reservoirs in the CNS. The goal of this project is to test whether the immunomodulation of innate-like and adaptive CD8 T cells via a novel IL-15 super-agonist (N-803) can significantly reduce HIV CNS reservoirs without causing neurotoxicity. Indeed, IL-15 promotes strong activation and expansion of HIV-specific CD8 T cells and improves their ability to kill reactivated HIV reservoir cells in vitro. IL-15 enhances memory CD8 T cell generation and persistence in tissues as well as trafficking to the CNS. IL-15 can also promote the conversion of CD8 T cells into antigen- independent innate-like effector cells, as well as the activation and expansion of NK cells. In nonhuman primates (NHP), IL-15 enhanced the function of SIV-specific CD8 T cell responses resulting in reduced plasma viral loads and increased the migration of SIV-specific CD8 T cells to B cell follicles. These results have supported the evaluation of IL-15 immunomodulatory potential in HIV remission strategies. However, the potential for IL-15 immunotherapy to reduce HIV persistence in the CNS remains unknown. In this project, we will study the impact of IL-15 on innate-like and adaptive CD8 T cells in two human HIV remission clinical trials in which participants receive N-803: the RV550 trial in Bangkok, Thailand, administering 3 doses of N-803 at time of ART initiation during acute HIV infection, and the ACTG A5386 trial administering 8 doses of N-803 in people with HIV on ART and undergoing an analytic treatment interruption. We will also conduct two NHP experiments following the design of the two human trials, that will provide us with access to brain tissue at necropsy. Collectively, these studies we allow us to determine whether N-803 administration in acute infection is safe for the CNS and can enhance HIV-specific CD8 T cell-mediated reduction of the CNS reservoirs. We will also determine whether repeated dosing of N-803 given during ART facilitates innate-like CD8 T cell-mediated reduction of CNS HIV reservoirs. These results should help define mechanisms by which CD8 T cells can clear HIV reservoirs from the CNS as well as CNS safety during an immunomodulatory intervention that may ultimately inform on the development of therapeutic strategies to eradicate the HIV reservoirs from the CNS. 1
项目总结 即使在抗逆转录病毒疗法(ART)存在的情况下,艾滋病毒仍长期存在于中枢神经系统(CNS)。 针对CNS艾滋病毒宿主的一种战略是开发干预措施,旨在提高广度和 数量巨大的CD8T细胞,它可以作为组织驻留细胞穿透并持续存在于大脑中。我们的团队已经 显示HIV特异性CD8 T细胞可以限制HIV在急性外周感染时的储存播种 是在急性感染期间启动的。我们已经开发了独特的工具来分析脑脊液中的这些细胞 在急性HIV感染期间,脑脊液(CSF)中也可以检测到HIV特异性CD8 T细胞 并在开始治疗后在脑脊液中坚持长达2年。重要的是,这些HIV特异性CD8的存在 T细胞对限制神经炎症是有益的,但还不足以完全消除中枢神经系统中的艾滋病毒蓄积物。 该项目的目标是测试先天类和适应性CD8 T细胞的免疫调节是否通过一种 新型IL-15超级激动剂(N-803)可以显著减少HIV中枢神经系统的储存,而不会造成神经毒性。 事实上,IL-15促进HIV特异性CD8 T细胞的强大激活和扩增,并提高它们的能力 在体外杀死重新激活的HIV储存细胞。IL-15增强小鼠记忆性CD8 T细胞的生成和持续时间 组织以及贩运到中枢神经系统。IL-15还能促进CD8 T细胞向抗原的转化。 独立的先天类效应细胞,以及NK细胞的激活和扩增。在非人类灵长类动物中 (NHP),IL-15增强SIV特异性CD8 T细胞反应的功能,从而降低血浆病毒载量 促进SIV特异性CD8T细胞向B细胞滤泡的迁移。这些结果支持了 评价IL-15在HIV缓解策略中的免疫调节潜力。然而,IL-15的潜力 减少艾滋病毒在中枢神经系统中持续存在的免疫疗法仍不清楚。在这个项目中,我们将研究其影响 在两项人类HIV缓解临床试验中,IL-15对先天和适应性CD8 T细胞的影响 接受N-803:在泰国曼谷进行的RV550试验,在抗逆转录病毒治疗开始时注射3剂N-803 在急性艾滋病毒感染期间,ACTG A5386试验对接受抗逆转录病毒治疗的艾滋病毒感染者给予8剂N-803 并接受分析治疗中断。我们还将进行两个NHP实验, 这两个人体试验的设计,将为我们提供在尸检时获取脑组织的途径。总而言之,这些 我们的研究使我们能够确定N-803治疗急性感染对中枢神经系统是否安全,以及 增强HIV特异性CD8 T细胞介导的中枢神经系统储备库的减少。我们还将确定是否 抗逆转录病毒治疗期间重复给予N-803促进先天类CD8 T细胞介导的中枢神经系统HIV的减少 水库。这些结果应该有助于确定CD8T细胞清除HIV储备库的机制 在免疫调节干预期间中枢神经系统以及中枢神经系统的安全性,最终可能会告知 制定治疗策略,从中枢神经系统根除艾滋病毒携带者。 1

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lishomwa C Ndhlovu其他文献

HIV-1 infection induces retrotransposition of LINE-1 elements
  • DOI:
    10.1186/1742-4690-6-s2-p43
  • 发表时间:
    2009-09-24
  • 期刊:
  • 影响因子:
    3.900
  • 作者:
    R Brad Jones;Keith E Garrison;Haihan Song;Anton Buzdin;Naveed Anwar;Duncan A Meiklejohn;Lishomwa C Ndhlovu;Douglas F Nixon;Mario A Ostrowski
  • 通讯作者:
    Mario A Ostrowski

Lishomwa C Ndhlovu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lishomwa C Ndhlovu', 18)}}的其他基金

Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection
确定针对儿童 HIV 感染中预防结核病而优化的持久 BCG 疫苗策略的免疫原性和功效
  • 批准号:
    10760444
  • 财政年份:
    2023
  • 资助金额:
    $ 97.44万
  • 项目类别:
Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence
IL-15 免疫疗法对组织特异性 CD8 T 细胞的影响,以减少中枢神经系统 HIV 储存库的播种和持久性
  • 批准号:
    10476697
  • 财政年份:
    2022
  • 资助金额:
    $ 97.44万
  • 项目类别:
HOPE - HIV Obstruction by Programmed Epigenetics
HOPE - 通过编程表观遗传学阻断 HIV
  • 批准号:
    10625421
  • 财政年份:
    2021
  • 资助金额:
    $ 97.44万
  • 项目类别:
HOPE - HIV Obstruction by Programmed Epigenetics
HOPE - 通过编程表观遗传学阻断 HIV
  • 批准号:
    10313946
  • 财政年份:
    2021
  • 资助金额:
    $ 97.44万
  • 项目类别:
HOPE - HIV Obstruction by Programmed Epigenetics
HOPE - 通过编程表观遗传学阻断 HIV
  • 批准号:
    10469610
  • 财政年份:
    2021
  • 资助金额:
    $ 97.44万
  • 项目类别:
Harnessing Single Cell Epigenome-wide profiling of Myeloid cells to Compare and Contrast Alzheimer's from HIV-Associated Cognitive Dysfunction
利用骨髓细胞的单细胞表观基因组分析来比较和对比 HIV 相关认知功能障碍引起的阿尔茨海默病
  • 批准号:
    10569610
  • 财政年份:
    2020
  • 资助金额:
    $ 97.44万
  • 项目类别:
Harnessing Single Cell Epigenome-wide profiling of Myeloid cells to Compare and Contrast Alzheimer's from HIV-Associated Cognitive Dysfunction
利用骨髓细胞的单细胞表观基因组分析来比较和对比 HIV 相关认知功能障碍引起的阿尔茨海默病
  • 批准号:
    10374058
  • 财政年份:
    2020
  • 资助金额:
    $ 97.44万
  • 项目类别:
Harnessing single cell epigenome-wide profiling of myeloid cells to compare and contrast Alzheimer's from HIV-associated cognitive dysfunction
利用骨髓细胞的单细胞表观基因组分析来比较和对比阿尔茨海默病与艾滋病毒相关的认知功能障碍
  • 批准号:
    10632875
  • 财政年份:
    2020
  • 资助金额:
    $ 97.44万
  • 项目类别:
Harnessing Single Cell Epigenome-wide profiling of Myeloid cells to Compare and Contrast Alzheimer's from HIV-Associated Cognitive Dysfunction
利用骨髓细胞的单细胞表观基因组分析来比较和对比 HIV 相关认知功能障碍引起的阿尔茨海默病
  • 批准号:
    10795252
  • 财政年份:
    2020
  • 资助金额:
    $ 97.44万
  • 项目类别:
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents
HIV SIV对青春期前结核分枝杆菌免疫中非常规T细胞的影响
  • 批准号:
    10582697
  • 财政年份:
    2019
  • 资助金额:
    $ 97.44万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.44万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.44万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 97.44万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.44万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 97.44万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.44万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.44万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.44万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 97.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 97.44万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了